CandlesenseCandlesense
News/Companies/MDWD

MDWD News

MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference

MDWD

YAVNE, Israel, August 20, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat, hosted by Swayampakula Ramakanth, Managing Director, Senior Equity Research Analyst, on Monday, September 8, 2025 at 4:30p.m. ET at the H.C. Wainwright 27th Annual Global Investment Conference.

August 20, 2025Conference
Read more →

HC Wainwright & Co. Maintains Buy on MediWound, Raises Price Target to $31

MDWD

May 22, 2025
Read more →

MediWound Q1 EPS $(0.07) Beats $(0.66) Estimate, Sales $3.96M Miss $5.20M Estimate

MDWD

May 21, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $25 Price Target

MDWD

March 20, 2025
Read more →

MediWound Expects 2025 Sales Of $25M Versus Consensus Of $24.98M

MDWD

March 19, 2025
Read more →

MediWound Q4 2024 GAAP EPS $(0.36) Beats $(0.59) Estimate, Sales $5.84M Beat $5.75M Estimate

MDWD

March 19, 2025
Read more →

Craig-Hallum Initiates Coverage On MediWound with Buy Rating, Announces Price Target of $39

MDWD

February 28, 2025
Read more →

MediWound Initiates VALUE Global Phase III Trial Of EscharEx In Treatment Of Venous Leg Ulcers

MDWD

February 12, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $25 Price Target

MDWD

January 10, 2025
Read more →

MediWound Highlights Inclusion Of NexoBrid In Presentations At 19th European Burns Association Congress

MDWD

September 12, 2022
Read more →